Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHeiq Regulatory News (HEIQ)

Share Price Information for Heiq (HEIQ)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 14.00
Bid: 13.30
Ask: 13.75
Change: 0.375 (2.75%)
Spread: 0.45 (3.383%)
Open: 13.95
High: 14.00
Low: 13.95
Prev. Close: 13.625
HEIQ Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

HeiQ Chrisal water treatment solution contract win

9 Jun 2021 07:00

RNS Number : 2259B
HeiQ PLC
09 June 2021
 

This article is not intended to be distributed in the USA.

 

9 June 2021

 

HeiQ Plc

("HeiQ" or "the Company")

 

HeiQ Chrisal sustainable water treatment solution contract win

 

HeiQ Plc (LSE:HEIQ), an established global brand in materials and textile innovation which operates in high-growth markets, is pleased to announce that its subsidiary, HeiQ Chrisal, which focuses on delivering industrial biotechnology solutions by incorporating the benefits of probiotics and synbiotics, has signed a partnership with Wöllner GmbH, one of Europe's leading suppliers of soluble silicates, process chemicals and specialty additives for industrial applications.

 

Under the terms of the distribution agreement, which will deliver revenues of at least €2 million to HeiQ Chrisal over a five-year period, Wöllner will offer its +150 customers an environmentally friendly, non-biocidal microbial management and cleaning solution developed by HeiQ Chrisal. The solution will be added to Wöllner's Process Enhancement Chemicals (PEC) product lines for industrial water circuits and Wöllner will have exclusivity over Germany, Austria, Switzerland, Finland, Denmark, Norway and Sweden in the defined field. Wöllner has selected HeiQ Chrisal's solution due to its ability to deliver superior efficiency, hygiene and sustainability benefits in comparison to alternative, chemical-based solutions.

 

Carlo Centonze, Co-founder & CEO of HeiQ Group, said: "This agreement is of strategic importance for HeiQ Chrisal, providing this innovative business access to the previously unentered arena of industrial water circuits. Wöllner continually focuses on providing its clients with high-quality and eco-friendly products for its customers and therefore, we are delighted that the team has recognized the superior results that environmentally friendly probiotics solutions can deliver. We believe that this is just the start of similar contracts which have the potential to deliver solid growth to HeiQ as we strengthen our presence in the $50 billion probiotics market."

 

Dr. Barbara März, CEO of Wöllner, said: "Innovation is the only answer to a more sustainable world and HeiQ Chrisal is at the very forefront of it. We are excited to partner with HeiQ Chrisal in delivering this innovative and environmentally friendly solution to our customers in industrial water circuits. We welcome all our customers to consult us for the planning and installation of dosing systems using such innovative and more environmentally friendly probiotic process enhancement technology."

 

For further information, please contact:

 

HeiQ Plc

Carlo Centonze (CEO)

+41 56 250 68 50

Arlington Group Asset Management Limited (Financial Advisor and Joint Broker)

Charles Cannon Brookes

+44 (0) 207 389 5017

Cenkos Securities plc (Joint Broker)

Stephen Keys / Callum Davidson

+44 (0) 207 397 8900

SEC Newgate (Media Enquiries)

Elisabeth Cowell / Robin Tozer / Megan Kovach

+44 (0) 20 3757 6882

HeiQ@secnewgate.co.uk

 

 

About HeiQ

HeiQ is focused on improving the lives of billions of people world-wide by innovating the materials people use every day. It is an IP-rich pioneer which is at the forefront of global technology in the $10 billion antimicrobial fabrics and $24 billion textile chemicals market. It has also moved into the medical device, healthcare and probiotics markets, to help make hospitals and healthcare environments more hygienic.

HeiQ has created some of the most effective, durable and high-performance technologies and textile effects in the market today, which cool, warm, dry, repel, purify, and destroy viruses. Since 2005, HeiQ has developed over 200 technologies in partnership with 300 major brands. It has won multiple awards and gained a strong reputation for sustainability.

Led by an experienced management team, HeiQ rapidly researches new solutions for partners, quickly delivers scaled up manufacturing from its sites across the world and helps partners market the product to end consumers - aiming for lab to consumer in months.

HeiQ aims to deliver growth for its shareholders through a combination of increased sales of its core products and by entering additional lucrative markets through disruptive innovations and M&A. It has a healthy R&D pipeline containing over 40 projects.

About Wöllner

Wöllner is one of Europe's leading suppliers of soluble silicates, process chemicals and specialty additives for industrial applications.

Wöllner has in-depth expertise in applied chemistry, covering the areas of research, development and production and continually invests in the development of high-quality and eco-friendly products and application systems.

Wöllner is a family-run enterprise with 125 years of experience, founded by Eduard Wöllner in 1896 in Ludwigshafen. It has three production sites in Germany and Austria and 150 professionals, including production, research & development, analytical & microbiological lab.  

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAUPUAUQUPGGQR
12
Date   Source Headline
28th Apr 20227:00 amRNSResults for the year ended 31 December 2021
14th Apr 20227:00 amRNSFY 2021 Trading Update and Notice of Results
24th Feb 20222:55 pmRNSIssue of Equity
17th Feb 20222:35 pmRNSDirector/PDMR Shareholding
14th Feb 20227:00 amRNSHUGO BOSS and LYCRA back new climate positive yarn
3rd Dec 20217:00 amRNSInvestor Presentation
28th Sep 20219:05 amRNSSecond Price Monitoring Extn
28th Sep 20219:00 amRNSPrice Monitoring Extension
28th Sep 20217:00 amRNSInterim Results
20th Sep 20217:00 amRNSNotice of Results and Investor Presentation
16th Jul 20217:00 amRNSCollaboration Agreement with The LYCRA Company
9th Jul 20217:00 amRNSCompletion of Acquisition
28th Jun 20211:45 pmRNSFurther re. Annual General Meeting
25th Jun 20214:40 pmRNSResult of AGM
21st Jun 20214:30 pmRNSAnnual General Meeting Update
15th Jun 20217:00 amRNSAcquisition Life Material Technologies Limited
9th Jun 20217:00 amRNSHeiQ Chrisal water treatment solution contract win
28th May 20217:00 amRNSCreates sustainable textile finishing partnership
20th May 20214:20 pmRNSProgressive initiates coverage
13th May 20217:00 amRNSNotice of AGM
29th Apr 20217:00 amRNSAcquisition of RAS AG
28th Apr 20217:00 amRNSResults for the year ended December 31, 2020
8th Apr 20217:00 amRNSNotice of Results and Investor Presentation
19th Mar 20217:00 amRNSHeiQ Viroblock Agreement with ICP
11th Mar 20217:00 amRNSHeiQ Viroblock Partnership with Berger Paint
3rd Mar 20217:00 amRNSAcquisition of 51% of Industrial Biotech Business
11th Feb 20217:00 amRNSHeiQ Viroblock Contract Win
28th Jan 202111:30 amRNSLaunch of HeiQ Viroblock Permanent
27th Jan 20219:05 amRNSSecond Price Monitoring Extn
27th Jan 20219:00 amRNSPrice Monitoring Extension
26th Jan 20219:05 amRNSSecond Price Monitoring Extn
26th Jan 20219:00 amRNSPrice Monitoring Extension
26th Jan 20217:00 amRNSTrading Update
13th Jan 20217:00 amRNSChange of External Auditor
5th Jan 20212:01 pmRNSPrice Monitoring Extension
4th Jan 20219:05 amRNSSecond Price Monitoring Extn
4th Jan 20219:00 amRNSPrice Monitoring Extension
15th Dec 20207:00 amRNSMajority stake in medical device manufacturer
9th Dec 202011:15 amRNSDirector/PDMR Dealings
9th Dec 20207:00 amRNSInvestor Presentation
7th Dec 20208:00 amRNSAdmission to Trading and First Day of Dealings
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.